+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Alzheimer's Disease: Competitive Landscape to 2026

  • ID: 4605706
  • Report
  • June 2018
  • Region: Global
  • 49 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3


  • AB Science
  • Archer Pharmaceuticals
  • AZTherapies
  • Eli Lilly
  • Intra-Cellular Therapies
  • Lundbeck
  • MORE
Alzheimer's Disease: Competitive Landscape to 2026


Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aß peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, the author expects new drug approvals to drive AD market growth over the next decade (2016-2026).


This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:
  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).
Reasons to buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3


  • AB Science
  • Archer Pharmaceuticals
  • AZTherapies
  • Eli Lilly
  • Intra-Cellular Therapies
  • Lundbeck
  • MORE
1. Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports

2. Executive Summary
2.2 Key Findings
2.2 Key Events

3. Introduction
3.1 Report Scope
3.2 Disease Overview and Epidemiology

4. Pipeline Assessment
4.1 Pipeline Overview
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Molecule Type and Target
4.4 Drug Review Designations
4.5 Products in Clinical Development

5. Clinical Trial Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in AD
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics

6 Commercial Assessment
6.1 Leading Marketed Products
6.2 Current & Future Players

7. Competitive Landscape Analysis (2016-2026)
7.1 Events Classification Overview
7.2 US
7.3 5EU
7.4 Japan
7.5 China

8 Appendix
8.1 Sources
8.2 Methodology
8.3 Key Events Included in the Analysis
8.4 About the Authors
8.5 About
8.6 Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Biogen
  • Eisai Co.
  • F. Hoffmann-La Roche
  • Otsuka Pharmaceuticals
  • Eli Lilly
  • Ionis Pharmaceuticals
  • TauRx Therapeutics
  • Axsome Therapeutics
  • Accera
  • Novartis
  • AZTherapies
  • AB Science
  • Grifols
  • Shanghai Green Valley Pharmaceutical
  • Archer Pharmaceuticals
  • Changchun Huayang High-Tech
  • Intra-Cellular Therapies
  • Avanir Pharmaceuticals
  • Promis Neurosciences
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • Janssen
  • Allergan
  • Adamas Pharmaceuticals
  • Lundbeck
  • Merz Pharma GmbH
  • Icure Pharmaceutical
  • Shire
  • Chase Pharmaceuticals
Note: Product cover images may vary from those shown